Correlation Between Microsoft and Franklin Genomic

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Microsoft and Franklin Genomic at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Microsoft and Franklin Genomic into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Microsoft and Franklin Genomic Advancements, you can compare the effects of market volatilities on Microsoft and Franklin Genomic and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Microsoft with a short position of Franklin Genomic. Check out your portfolio center. Please also check ongoing floating volatility patterns of Microsoft and Franklin Genomic.

Diversification Opportunities for Microsoft and Franklin Genomic

0.2
  Correlation Coefficient

Modest diversification

The 3 months correlation between Microsoft and Franklin is 0.2. Overlapping area represents the amount of risk that can be diversified away by holding Microsoft and Franklin Genomic Advancements in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Franklin Genomic Adv and Microsoft is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Microsoft are associated (or correlated) with Franklin Genomic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Franklin Genomic Adv has no effect on the direction of Microsoft i.e., Microsoft and Franklin Genomic go up and down completely randomly.

Pair Corralation between Microsoft and Franklin Genomic

Given the investment horizon of 90 days Microsoft is expected to under-perform the Franklin Genomic. In addition to that, Microsoft is 1.08 times more volatile than Franklin Genomic Advancements. It trades about -0.04 of its total potential returns per unit of risk. Franklin Genomic Advancements is currently generating about 0.0 per unit of volatility. If you would invest  3,095  in Franklin Genomic Advancements on August 30, 2024 and sell it today you would lose (6.00) from holding Franklin Genomic Advancements or give up 0.19% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Microsoft  vs.  Franklin Genomic Advancements

 Performance 
       Timeline  
Microsoft 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Microsoft are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable technical and fundamental indicators, Microsoft is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
Franklin Genomic Adv 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Franklin Genomic Advancements has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Etf's essential indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the ETF investors.

Microsoft and Franklin Genomic Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Microsoft and Franklin Genomic

The main advantage of trading using opposite Microsoft and Franklin Genomic positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Microsoft position performs unexpectedly, Franklin Genomic can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Franklin Genomic will offset losses from the drop in Franklin Genomic's long position.
The idea behind Microsoft and Franklin Genomic Advancements pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets